导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -11.65% | 3903/4773 |
| 近一周 | -1.89% | 1839/5458 |
| 近一月 | -2.57% | 1605/5421 |
| 近一季 | -1.72% | 1473/5205 |
| 近半年 | -12.35% | 3811/4920 |
| 近一年 | -14.43% | 3682/4361 |
| 近两年 | 30.81% | 2277/2954 |
| 近三年 | 14.67% | 1652/2253 |
| 成立以来 | 61.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.34% 4102/4961 |
-10.04% 4031/5312 |
- - |
- - |
| 2025 | 18.49% 2310/4813 |
6.75% 580/3635 |
-0.70% 3006/4076 |
18.06% 2358/4524 |
-5.33% 3537/4813 |
| 2024 | 18.33% 610/3463 |
1.75% 857/2808 |
1.29% 483/3014 |
15.15% 1800/3129 |
-0.30% 1374/3463 |
| 2023 | -7.13% 893/2656 |
6.83% 639/2280 |
-4.19% 1088/2385 |
-4.11% 1064/2515 |
-5.38% 1335/2655 |
| 2022 | -9.75% 184/2207 |
-7.97% 266/1919 |
2.73% 1265/2016 |
-11.14% 497/2113 |
7.43% 311/2208 |
| 2021 | 6.60% 511/1822 |
4.59% 144/1255 |
3.35% 974/1330 |
-0.34% 489/1466 |
-1.04% 1301/1822 |
| 2020 | 22.08% 677/1250 |
-8.40% 605/1028 |
15.59% 484/1067 |
6.64% 822/1164 |
8.13% 688/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏AH经济蓝筹股票A VS. 长安沪深300非周期A(740101) |